Table 4.
The publication bias assessment of the included studies.
| Parameters | No. of Studies/Cohorts | Begg Test (p-Value) |
Egger Test (p-Value) |
Model |
|---|---|---|---|---|
| PARPs and survival outcomes | ||||
| Overall Survival | 24/26 | 0.133 | 0.024 * | Fixed |
| Disease-free survival | 14 | 0.062 | 0.001 * | Fixed |
| Progression-free survival | 7/8 | 0.536 | 0.455 | Fixed |
| PARPs and clinicopathological parameters | ||||
| Age (>50 vs. <50) | 8 | 0.063 | 0.017 * | Fixed |
| Tumour size (>5 cm vs. <5 cm) |
8 | 1.000 | 0.723 | Fixed |
| Histologic grade (1 + 2 vs. 3) | 4 | 0.308 | 0.345 | Fixed |
| T stage (1 + 2 vs. 3 + 4) | 17 | 0.964 | 0.532 | Fixed |
| Lymph node metastasis (absent vs. present) | 6 | 1.000 | 0.804 | Fixed |
| Distant metastasis (absent vs. present) |
6 | 0.259 | 0.354 | Fixed |
| TNM stage (I + II vs. III + IV) | 10 | 1.000 | 0.513 | Fixed |
| PARPs and Immunohistological markers | ||||
| Ki-67 (negative vs. positive) | 5 | 0.220 | 0.113 | Fixed |
| BRCA1 (negative vs. positive) | 4 | 0.308 | 0.368 | Fixed |
| BRCA2 (negative vs. positive) | 3 | 1.000 | 0.370 | Fixed |
*: Significant p-value.